Gsk (GSK) Price to Earnings (2026)

Gsk (GSK) has 18 years of Price to Earnings data on file, last reported at 10.85 in Q3 2026.

• For the quarter ending Q3 2026, Price to Earnings changed N/A year-over-year to 10.85; the trailing twelve-month figure through Sep 2026 stood at 10.85 (changed N/A YoY), and the FY2025 full-year result was 13.92, down 37.21% from the prior year.
• Price to Earnings was 10.85 for Q3 2026 at Gsk, down from 11.64 in the prior quarter.
• In the past five years, Price to Earnings ranged from a high of 13.36 in Q3 2024 to a low of 3.24 in Q3 2022.
• A 5-year average of 9.39 and a median of 10.09 in 2022 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings plunged 65.48% in 2022 and surged 173.97% in 2023, its largest moves.
• Gsk's Price to Earnings stood at 3.92 in 2022, then soared by 113.15% to 8.36 in 2023, then soared by 56.46% to 13.07 in 2024, then dropped by 24.83% to 9.83 in 2025, then gained by 10.42% to 10.85 in 2026.
• Per Business Quant data, the three most recent Price to Earnings figures were 10.85 in Q3 2026, 11.64 in Q2 2026, and 10.76 in Q1 2026.